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Background: The European Quality of Life in Short Stature Youth (QoLISSY) is a novel condition-specific instrument
developed to assess health related quality of life (HrQoL) in children/adolescents with short stature from patient
and parent perspectives. Study objective was to linguistically validate and psychometrically test the American-
English version of the QoLISSY instrument.
Methods: Upon conversion of the British-English version to American-English, content validity and acceptance of the
questionnaire were examined through focus group discussions with cognitive debriefing in 28 children/adolescents
with growth hormone deficiency (GHD) or idiopathic short stature (ISS) and their parents. In the subsequent field test
with 51 families and a re-test with 25 families the psychometric performance of the American-English version was
examined and compared with the original European dataset.
Results: Pilot test results supported the suitability of the American-English version. Good internal consistency with
Cronbach’s Alpha ranging from 0.84 to 0.97 and high test-re-test reliabilities were observed in the field test. The
QoLISSY was able to detect significant differences according to the degree of short stature with higher HrQoL for taller
children. Correlations with a generic HrQoL tool support the QoLISSY’s concurrent validity. The scale’s operating
characteristics were comparable to the original European data.
Conclusion: Results support that the QoLISSY American-English version is a psychometrically sound short stature-
specific instrument to assess the patient- and parent- perceived impact of short stature. The QoLISSY instrument is fit
for use in clinical studies and health services research in the American-English speaking population.
Keywords: Short stature, Health related quality of life, Children, Questionnaire development, Psychometric propertiesIntroduction
Health-related Quality of Life (HrQoL) is an important
multidimensional concept that is often measured in
pediatric patients and instruments to measure this are in-
creasingly being developed for that purpose. A literature re-
view by Brutt, A.L., Sandberg, D.E., Chaplin, J., Wollmann,
H., Noeker, M., Koltowska-Haggstrom, M. and Bullinger,
M. [1] identified five pediatric condition-specific instru-
ments available for use in children and adolescents with
short stature. According to the authors, none of these mea-
sures provides adequate assessment of all domains* Correspondence: andreas.m.pleil@pfizer.com
2Pfizer Inc., Outcomes Research, San Diego, CA, USA
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unless otherwise stated.potentially relevant to the condition. Therefore, the purpose
of the European QoLISSY (Quality of Life in Short Stature
Youth) effort was to develop cross-culturally and psycho-
metrically test a questionnaire that utilizes a multifactorial
approach to evaluate the impact of short stature on chil-
dren and adolescents, from both the child and parent
perspectives.
The original QoLISSY questionnaire was developed
along a common study protocol in five European coun-
tries and respective languages (UK, Spain, France, Sweden
and Germany). Clinically referred children and adoles-
cents diagnosed with growth hormone deficiency (GHD)
or idiopathic short stature (ISS) and their parents were in-
cluded in the study. To make the QoLISSY questionnaireal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lescents with short stature living in the US, it is necessary
to examine the instrument both in terms of conceptual
equivalence as well as psychometric performance. The
aim of the present study is the translation and psychomet-
ric evaluation of the QoLISSY instrument for use in the
US.
Health-related quality of life (HrQoL) in short stature
Health-related Quality of Life reflects the impact of
chronic diseases and disabilities on wellbeing and func-
tioning of patients and their families. Assessments of
HrQoL can help to increase our understanding of the
burden of disease, examine treatment outcomes, evalu-
ate quality of care and assist in tailoring interventions
according to patients’ needs [2].
Generic HrQoL assessment makes it possible to com-
pare HrQoL along the health continuum and across dif-
ferent health conditions [3]. Generic measures, however,
may not be sensitive enough to detect smaller changes
in HrQoL and may not cover all relevant domains for
the respective disorder. Targeted HrQoL instruments
focus on the impact of the condition; hence offering a
deeper insight into the HrQoL of patients with a specific
impairment, condition, or disorder. But, since those in-
struments are specific to a defined health condition,
their use for comparisons between different conditions
is limited [3].
Health-related Quality of Life can be measured either
by patient-report or by observer-report of a significant
other such as a parent, other caregiver or clinician. Par-
ent reports, however, do not necessarily reflect the
child’s entire perspective, especially when evaluating the
children’s feelings such as anxieties, or behaviors such as
interactions with peers [4]. Studies suggest that parents
of healthy children tend to overestimate, while parents
of ill children underestimate their children’s quality of
life but the direction of divergence can vary across
chronic conditions [5,6].
Instruments to assess HrQoL exist for different age
groups, but younger children are underrepresented [7].
Only one instrument (TACQOL-S) [8] identified in the
review by Brutt, A.L., Sandberg, D.E., Chaplin, J.,
Wollmann, H., Koltowsa-Haggestrom, M., Bullinger, M.
[1] is available in three languages, which makes cross-
cultural comparisons difficult [9]. To gain more insight
into the HrQoL of children, especially those with short
stature, the development of targeted instruments is
necessary, such as the QoLISSY questionnaire, to assess
their HrQoL [10].
Short stature
Short stature is commonly defined as a height 2.0 or
more standard deviations (SD) below the population-specific mean height for age and gender. Endocrine and
non-endocrine causes for short stature have been identi-
fied, including growth hormone (GH) deficiency (GHD),
which can occur both alone or in combination with
other pituitary hormone deficits and is treated by GH re-
placement [11]. However, about 50% of children fulfilling
the statistical definition of short stature, have no identifi-
able underlying endocrine or other disorder and are des-
ignated as Idiopathic Short Stature (ISS) [12]. These
children are born with normal length and weight
(> − 2.0 SD), have low growth velocity but show no evi-
dence of hypothyroidism, malnutrition or lack of GH
[13]. Treatment with GH in children with ISS may result
in an increase in height but the responses are more vari-
able than in GHD [14].Psychosocial consequences of short stature
Height has been found to be a factor affecting the HrQoL
of adults on a population level [15]; however, similar epi-
demiological studies in children are lacking. In the case of
health-referred children with short stature, studies have
identified socio-emotional problems. In a study from Voss
and Mulligan [15] for example, short children reported
that they were bullied frequently [16]. Short stature has
also been reported to be associated with stigmatization
and social isolation which can cause chronic psychosocial
stress [17]. Though these experiences do not necessarily
result in clinically relevant problems, parents report their
children to be less socially competent and to generally
have more problems of a social nature than parents of
children with normal height [18]. Children with GHD or
ISS have also been shown to exhibit social and physical
functioning limitations as assessed with the Child Behav-
ior Check List [19].
A German study compared short statured children
with a group of children of normal height using the
KIDSCREEN 52, a generic self-report instrument to as-
sess quality of life [20]. Short statured children scored
significantly lower on most scales, e.g. Psychological
Well-being, Self-Perception and Social Support & Peers,
but did not significantly differ from the non-short chil-
dren on the Parent Relations & Home Life and Financial
Resources scales [17].
Other studies examined if growth hormone treatment
increases wellbeing and functioning. Abe et al. [20] re-
ported that depressive mood in children with GHD im-
proved with growth hormone treatment. Chaplin et al.
[21] reported significant treatment benefits regarding be-
havioral problems and depressive mood with GH. Zlotkin
and Varma [22] reviewed four studies and concluded that
there is an increase in wellbeing in children receiving
growth hormone treatment, especially in those diagnosed
with GHD [23].
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cm compared to a control group for ISS and Small for
Gestational Age (SGA) patients, but no differences in self-
reported height-related psychosocial problems. Interest-
ingly, most of the subjects, treated and untreated, were
happy with their achieved height [24]. Sandberg and
Colsman suggested that psychosocial problems in children
with short stature are common phenomena and do not
necessarily result from short stature [25].
Health-related Quality of Life instruments have rarely
been used in comparative trials, so that information on
HrQoL in short statured children as an indicator of
treatment efficacy, particularly in the context of clinical
efficacy trials of GH treatment, is missing. One reason
for this is unavailability of an appropriate measure to
assess HrQoL across languages and cultures. The
condition-specific QoLISSY questionnaire was devel-
oped to fill this gap [9]. The current study describes the
adaptation of the QoLISSY to American-English and
examines its operating characteristics and psychometric
properties.Methods
Within the cultural adaptation, the original British-
English QoLISSY version was modified by independent
native American-English speakers. The American-English
pilot version resulted in nominal wording changes in the
response categories only. These were: ‘Almost never’ (US)
was used instead of ‘Seldom’ (UK) as well as ‘Sometimes’
(US) instead of ‘Quite often’ (UK) and ‘Almost always’
(US) instead of ‘Very often’ (UK). Procedures originally
applied within the European QoLISSY project were also
used in the current validation process [9], which was
performed in cooperation with four pediatric endocrine
clinics in the US. In the first phase of the study, patients
and parents participated in separate moderator-supported
focus group sessions/discussions. Afterwards, these
patients and parents separately completed the QoLISSY
questionnaire and subsequently participated in a cogni-
tive debriefing exercise. During the debriefing, they were
specifically asked to evaluate the items in terms of clarity,
sensitivity, importance, and relevance for their personal
situation. The transcripts of the discussions were ana-
lyzed and questionnaires were modified according to the
results. The resulting American-English QoLISSY ques-
tionnaire was used in the second phase of the study, in
which a field test was conducted in children with GHD
or ISS and their parents who were recruited from the
participating clinical centers. Questionnaires were distrib-
uted to participating families and returned to the sites. A
second set of questionnaires was mailed to the partici-
pants approximately two weeks later to provide a re-test
reliability dataset.Inclusion and exclusion criteria
Short statured children between eight and 18 years of age
and one or both of their parents were invited to participate
in the validation study. In addition, the parents of younger
children (those between four and seven years) were in-
cluded. All children had a clinical diagnosis of either ISS or
GHD. Children with multiple hormone deficiencies or se-
vere mental or physical conditions were excluded. Children
could be either untreated or treated with GH for varying
durations. The study was approved by each center’s institu-
tional review committee and parents signed an informed
consent before participation, while children and adoles-
cents additionally signed an assent form if required.
Questionnaires
The QoLISSY instrument consists of three core scales
which cover Physical (six items), Social (eight items) and
Emotional (eight items) aspects of functioning and well-
being in child- and parent-report. Furthermore, to iden-
tify potential determinants of HrQoL three additional
scales that cover aspects of Coping (ten items), general
Beliefs about height (five items) and Treatment specific
aspects (for GH-treated children and their parents only,
14 items). Two additional scales apply to and are com-
pleted by parents only. They contain questions about the
child’s future (four items) and Effects of their child’s
short stature on parents (eleven items). Based on scoring
rules of standard HrQoL measures [26] and in line with
the European QoLISSY manual, the QoLISSY Total
Score is calculated as a mean of the three core module
means. If 80% or more of all items in a scale are com-
pleted by the respondent, the scale score mean was cal-
culated as the mean of the endorsed items, otherwise
the scale score and the resulting Total Score were
treated as missing.
The KIDSCREEN Index questionnaire measuring
HrQoL from both patients and parents perspective was
included as a generic measure to examine convergent
validity of the QoLISSY for psychometric testing pur-
poses as a reliable and valid generic instrument [27].
Socio-demographic and clinical data were collected by
the clinical centers including age, gender, diagnosis,
height, treatment status, duration of treatment, date of
treatment start.
Analysis
Data collected from the focus groups were processed
using MaxQDA, a qualitative data analysis program
(VERBI-Software MaxQDA 10). Parallel coding involving
two trained coding experts was used. For each statement
inter-observer agreement was discussed and the few dis-
agreements in statement codings were resolved by con-
sensus. The purpose of the field test and re-test, which
followed, was to evaluate the operating characteristics for
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English questionnaire. Item distribution characteristics
such as mean (M), standard deviation (SD), percentage of
items at the lower (floor effects) and the higher end (ceil-
ing effects), skewness as well as discriminatory power of
the scales were inspected. Two indices for internal
consistency were measured: split-half reliability and
Cronbach’s alpha. Scores above 0.70 were interpreted as
acceptable [28]. Test re-test reliability was calculated with
the intra-class correlation coefficient (ICC, r) for each
scale and the total score in both the parents’ and the
children’s version. Intra Class coefficients between 0.40
and 0.75 indicate fair to good reliability and above 0.75 ex-
cellent reliability [29].
To test for convergent validity, the QoLISSY scale scores
were correlated with the KIDSCREEN Index in the patient-
report and the parent report version (Pearson’s Correlation
Coefficient). In line with Weber J and Lamb D [30] scores
between r = 0.36 and r = 0.67 were interpreted as moderate.
Scores between r = 0.68 to r = 0.90 indicate high correla-
tions and scores above 0.90 indicate very high correlations.
In line with published research suggesting effects of clinical
characteristics on HrQoL, known-groups validity was tested
based on the degree of short stature (≤ −2.0SD, > − 2.0SD).
Differences in treatment status were not analyzed due to
the small number of untreated children/ adolescents.
Finally, differences according to patients’ gender and
age were evaluated in order to examine the need for re-
spective adjustments in scoring. Convergence of operat-
ing characteristics between the European and the US
samples was inspected albeit limited in that the samples,
though similar, were not necessarily equivalent.
Results
Focus groups
To ensure that this study used a method similar to the
one used in the original European study, a focus group




Gender Male 35 (68.6%) 41 (68.3%) 6 (66.7%
Female 16 (31.4%) 19 (31.7%) 3 (33.3%
Diagnosis ISS 26 (51.0%) 32 (53.3%) 6 (66.7%
GHD 25 (49.0%) 28 (46.7%) 3 (33.3%
Treatment Treated 46 (90.2%) 55 (91.7%) 9 (100%
Untreated 5 (9.8%) 5 (8.3%) 0 (0%)
SD height > − 2.0 31 (60.8%) 35 (58.3%) 4 (44.4%
≤ − 2.0 20 (39.2%) 25 (41.7%) 5 (55.5)
*Only parents completed the questionnaire for children aged 4–7.guidelines, was prepared. Bi-lingual trained moderators
(psychologists, medical staff ) from Europe and the US
conducted initial interviews. The focus group discus-
sions and interviews were transcribed verbatim and ana-
lyzed by two independent raters, using the qualitative
content analysis program MAX QDA [31]. The detailed
results of the qualitative analyses will be published in a
subsequent paper.
Focus groups with cognitive debriefing included 24 chil-
dren and adolescents and 28 parents. Overall, the qualita-
tive analyses of the focus group responses produced no
new concepts or topics, nor excluded any topics of rele-
vance when compared with the results of the original
European focus groups. The cognitive debriefing ques-
tions for children/adolescents resulted only in nominal
wording changes. For example: ‘I am concerned that (s)he
will be hurt by any insults about his/ her height’ (US) was
used instead of ‘Because of my child’s height I am con-
cerned that (s)he will be hurt by the insults’ (UK). For the
focus group and cognitive debriefing phase the 5-point
Likert-like response category labels were adapted to an
American-English format from the commonly used British-
English form of the scale point labels.
Field-test
A total of 60 families participated on the field test with
51 sets of responses received from the parent and 50 sets
of their child/adolescent and nine questionnaires from
exclusively the parents of children between four to seven
years of age; one boy in the age group 13–18 did not an-
swer the QoLISSY child version in the field test. Male
patients outnumbered females about 2:1 and this was
consistent across age groups. In total, 28 children were
diagnosed with GHD and 32 with ISS, 55 patients were
treated with GH, and 5 patients were untreated (see
Table 1). At the time of the field test data collection, 25
children still met the criteria for short stature with a
standard deviation (SD) below −2.0; while 35 had grownup
rs 8-12 years 13-18 years
only * Child Parent Child Parent
) 12 (54.5%) 12 (54.5%) 23 (79.3%) 23 (79.3%)
) 10 (45.5%) 10 (45.5%) 6 (20.6%) 6 (20.7%)
) 13 (59.1%) 13 (59.1%) 13 (42.9%) 13 (44.8%)
) 9 (40.9%) 9 (40.9%) 16 (57.1%) 16 (55.2%)
) 20 (90.9%) 20 (90.9%) 26 (89.3%) 26 (89.7%)
2 (9.1%) 2 (9.1%) 3 (10.7%) 3 (10.3%)
) 13 (59.1%) 13 (59.1%) 18 (62.1%) 18 (62.1%)
9 (40.9%) 9 (40.9%) 11 (37.9%) 11 (37.9%)
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families who had participated in the field test were asked
to complete a retest questionnaire two weeks later. A
total of 25 out of 51 families returned the questionnaire
for this purpose.
In terms of mean (M), standard deviation (SD), range and
floor and ceiling effects scale characteristics of the
American-English version of the self- and parent-report
show a slight skew to the right, favoring a higher QoL within
the range of 0 to 100 (with 100 reflecting the highest QoL).
Cronbach’s alpha measure of internal consistency across all
QoLISSY scales ranged between α= 0.57 (Coping) to
α = 0.96 (QoL Total Score) for the child/adolescent version
(Table 2) and from α= 0.87 (Treatment) to α= 0.97 (QoL
Total Score) for the parent version (Table 3). Test-re-test-re-
liability ranged from r= 0.475 (Emotional QoL) up to
r= 0.815 (Physical QoL) for the patient reported version and
from r= 0.549 (Treatment and Coping) up to r= 0.893
(Physical QoL) for the parent reported version. Satisfactory
instrument reliabilities were found in the children‘s/adoles-
cent’s (Table 2) and the parent version of the QoLISSY ques-
tionnaire (Table 3). Comparison of Cronbach’s alpha of theTable 2 Descriptive statistics and reliability estimates on QoL
European sample (children)
Children Descriptive statistics
N Mean SD Skewness %
Physical* 49 75.54 19.89 −0.91 2
US sample
European sample 268 73.69 20.08 −0.95 0
Social* 50 71.42 20.72 0.21 2
US sample
European sample 268 72.94 22.93 −0.79 0
Emotional* 50 73.13 19.35 −0.84 2
US sample
European sample 268 72.69 23.87 −0.94 1
Coping 48 50.46 20.61 0.25 2
US sample
European sample 257 55.60 22.38 −0.19 1
Beliefs 49 69.34 27.40 −0.75 2
US
European sample 266 69.13 28.59 −0.78 3
Treatment 43 49.82 19.06 0.32 2
US
European sample 152 55.12 21.06 −0.13 0
QoL Total Score 49 73.75 21.35 −0.82 2
US sample
European sample 268 73.10 21.39 −0.80 0
*The QoL total Score is the sum of the physical, social and emotional scale.
**If item three is deleted, Cronbachs alpha would be 0.81.US with the European data set, as shown in Tables 2 and 3,
suggests equivalence in the reliability of the instrument.
Construct validity was determined using convergent
and known-groups validity. Significant correlations in
the mean range with the KIDSCREEN Index, as an indi-
cator of convergent validity, were found for the QoLISSY
Physical (r = 0.36), Social (r = 0.33) and Emotional scale
(r = 0.29) in patient self-report, but only for the QoLISSY
Emotional scale (r = 0.36) in parent-report. Similar cor-
relation coefficients, indicating less than 10% of shared
variance, were found in the European data set (see
Table 4).
Known groups validity was analyzed by comparing pa-
tient subgroups according to height (≤ −2.0 SD vs. > −2.0
SD). Differences in mean scores of each of the QoLISSY
scales were analyzed separately for the patient and the
parent-reported version of the questionnaire (Table 5).
In the child/adolescent reported QoLISSY, significant
differences between the groups based on height were
found in the following scales: Physical (p = 0.043) Social
(p = 0.009) and Emotional (p = 0.044), confirming that
taller children have better quality of life, as would beISSY scale level for the US sample in comparison with the
Reliability
Floor % Ceiling N α Split-half ICC
.0 8.2 48 0.85 0.87 0.82
.4 12.3 263 0.84 0.83 0.80
.0 8.0 49 0.92 0.94 0.69
.4 10.4 265 0.87 0.83 0.80
.0 10.0 49 0.89 0.95 0.48
.1 10.1 259 0.88 0.88 0.85
.1 2.1 45 0.57** 0.53 0.77
.2 1.2 244 0.82 0.65 0.56
.0 22.4 49 0.87 0.87 0.59
.8 21.1 263 0.85 0.85 0.83
.3 2.3 41 0.84 0.70 0.67
.7 0.7 143 0.87 0.74 0.73
.0 2.0 47 0.96 0.93 0.72
.4 4.9 251 0.95 0.92 0.88
Table 3 Descriptive statistics and reliability estimates on QoLISSY scale level for the US sample in comparison with the
European sample (parents)
Parents Descriptive statistics Reliability
N Mean SD Skewness % Floor % Ceiling N α Split-half ICC
Physical* 60 70.39 21.92 −0.50 1.7 10.0 59 0.91 0.86 0.89
US sample
European sample 317 71.80 23.20 −0.76 1.3 13.2 310 0.86 0.86 0.84
Social* 60 65.92 26.02 −0.41 3.3 11.7 59 0.95 0.94 0.82
US sample
European sample 313 69.41 25.24 -.60 0.3 12.5 308 0.90 0.88 0.84
Emotional* 59 68.05 22.11 −0.62 1.7 6.8 56 0.92 0.92 0.80
US sample
European sample 315 68.50 22.90 −0.66 0.3 5.4 309 0.88 0.90 0.70
Coping 56 40.27 23.41 −0.10 10.7 1.8 54 0.91 0.84 0.55
US sample
European sample 286 45.07 20.96 0.03 3.1 0.7 276 0.86 0.65 0.65
Beliefs 58 62.72 31.72 −0.36 1.7 20.7 58 0.94 0.94 0.78
US sample
European sample 310 67.62 28.95 −0.62 2.6 22.3 310 0.90 0.89 0.72
Treatment 54 52.73 19.35 0.09 1.9 1.9 52 0.87 0.74 0.55
US sample
European sample 163 55.18 20.60 −0.23 0.6 1.2 154 0.88 0.78 0.74
Future US sample 59 73.73 25.40 −0.90 1.7 23.7 59 0.94 0.92 0.85
European sample 303 74.85 26.45 −0.1.1 1.3 20.5 297 0.90 0.86 0.74
Effects on parents 60 64.80 22.68 −0.68 3.3 1.7 59 0.90 0.85 0.71
US sample
European sample 313 65.68 24.48 −0.44 1.6 5.1 261 0.90 0.82 0.88
QoL Total Score 59 68.31 22.14 −0.50 1.7 1.7 54 0.97 0.94 0.85
US sample
European sample 313 69.97 22.03 −0.65 0.3 2.9 296 0.95 0.91 0.86
*The QoL total Score is the sum of the physical, social and emotional scale.
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discriminant validity (p = 0.035).
The parent-report version analysis yielded comparable
results in that group differences based on height SD
were found for the Physical (p = 0.001), Social (p = 0.001)
and the QoL Total Score (p = 0.003), but failed to reach
significance in the scale Emotional. These results reflect
similar findings from the European data regarding height
(data not shown here) [32].
Discussion
The translation and psychometric testing of the
American-English version of the European QoLISSY
questionnaire was conducted following generally ac-
cepted (FDA) guidelines for instrument validation [33].
Qualitative focus group discussions did not yield any
novel differences, indicating conceptual equivalence andcomparability of the short stature experience between
the American-English and the European sample. Cogni-
tive debriefing results support that the instrument is ac-
ceptable and understandable to children/adolescents and
parents in the US. The pilot test results were sufficiently
robust to allow for the larger field test without the need
for additional changes to the instrument. The field test
data show results that were psychometrically satisfac-
tory, including good operating characteristics, sufficient
evidence of reliability, and acceptable evidence of con-
struct validity in the child-report. The lowest ICCs we
observed were between 0.48 and 0.69 in child-report and
0.55 and 0.71 in parent-report. According to Rosner, B.
[29] these can be considered as fair to good. The poor
internal consistency of the child-reported Coping scale
is due to one item which may have been misunderstood
by the respondents. We decided to keep rather than
Table 4 Correlations between QoLISSY scales and KIDSCREEN Index in the US sample in comparison with the European
sample
QoLISSY scales KIDSCREEN KIDSCREEN
Index (patient completed) Index (parent completed)
N = 46 N = 59
Physical 0.36* 0.18
US sample
European sample 0.25** 0.23**
Social 0.33* 0.22
US sample
European sample 0.27** 0.21**
Emotional 0.29* 0.36**
US sample
European sample 0.31** 0.30**
Coping −0.04 0.02
US sample
European sample 0.14 0.21**
Beliefs 0.12 0.25
US sample
European sample 0.32** 0.21**
Treatment −0.02 0.16
US sample
European sample 0.13 0.11
Future US sample n.a. 0.29*
European sample n.a 0.17**
Effects on Parents n.a 0.24
US sample
European sample n.a 0.17**
QoL Total Score 0.34* 0.279*
US sample
European sample 0.30** 0.27**
*Pearson Correlation Coefficient “r” is significant at the 0.05 level (2-tailed).
**Pearson Correlation Coefficient “r” is significant at the 0.01 level (2-tailed).
n.a. not applicable, since scales were completed by parents only.
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the appropriately performing parent-report and the
European data set. A modification of the item for future
studies will be considered. Significant positive correla-
tions between the three QoLISSY core scales and the
KIDSCREEN Index suggest convergent validity, however,
with a percentage of shared variance below 10% for
child-reported values. For the parent-report, no evidence
of convergent validity could be found. These results
support the need for the development of a condition-
specific tool such as the QoLISSY questionnaire. Signifi-
cant group differences in the scales for both the child
and parent cohorts, based on the degree of short stature,
are evidence of discriminant validity. The scales Physical,Social and Emotional confirm that taller children have
better quality of life, as would be expected. The total score
provided similar evidence of discriminant validity. Com-
paring distributional characteristics of the American-
English sample with the European sample supports the
equivalence of the measure in the two populations. Add-
itionally, inspection of coefficients for reliability (internal
consistency and test-re-test) as well as validity (convergent
and known groups) supports comparability of psychomet-
ric performance of the QoLISSY in the American-English
and European samples. These findings further underscore
the results of the cognitive debriefing and suggest that the
conceptual framework of short stature is consistent across
the western cultures of Europe and the US. How this
Table 5 Differences in QoLISSY scales according to height deviation (t-test) in child report and in parent report
Height > −2.0 SD Height ≤ −2.0 SD
(taller) (shorter)
Scale n Mean* SD n Mean* SD t df p
Physical
Child report1 30 80.97 14.99 19 66.97 23.80 −2.53 47 0.015
Parent report 35 79.12 17.80 25 58.16 21.57 −4.11 58 0.001
Social
Child report 30 79.27 19.77 20 59.64 28.25 −2.90 48 0.006
Parent report 35 75.06 22.57 25 53.13 25.50 −3.52 58 0.001
Emotional
Child report1 30 79.69 15.91 20 63.28 27.99 −2.38 27.2 0.025
Parent report 35 72.23 19.84 24 61.94 24.18 −1.79 57 0.079
Coping
Child report 28 45.06 17.45 20 58.03 42.47 1.46 46 0.152
Parent report 34 36.25 24.00 22 46.48 21.53 1.62 54 0.111
Beliefs
Child report 29 73.71 23.59 20 63.13 30.27 −1.37 47 0.176
Parent report 35 66.61 30.31 23 56.79 33.55 −1.16 56 0.253
Treatment
Child report 28 48.71 15.47 15 51.90 20.15 0.580 41 0.565
Parent report 33 55.98 19.83 21 47.62 17.85 −1.57 52 0.123
Future
Parent report 35 78.43 23.16 24 66.88 27.42 −1.75 57 0.086
Effects on Parents
Parent report 35 67.40 23.16 25 61.16 21.94 −1.05 58 0.298
Total Score
Child report1 30 79.98 15.45 19 63.92 25.76 −2.45 26.3 0.021
Parent report 35 75.47 19.03 24 57.87 22.57 −3.23 57 0.002
The Scales “Future” and “Effects on Parents” only exist in the parents’ version.
1Levene’s test for variance homogeneity is significant with p < .05.
*Minimum = 0, maximum = 100; the higher the better.
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be evaluated.
Limitations
The sample size in this study was too small to conduct a
confirmatory factor analysis, but sufficient for the pur-
poses of descriptive comparisons of psychometric char-
acteristics between the US and the European QoLISSY
versions. Future studies with sufficient sample sizes are
needed to conduct a confirmatory factor analysis for the
US QoLISSY version. Three geographical regions in the
US were represented, but only English speaking subjects
were included in the current analysis. The American-
Spanish version of the QoLISSY, specifically one that
considers the possible cultural differences of a Spanish-
American population, may be necessary if one would
apply this measure to this large segment of the USpopulation. In addition, while appropriately weighted
in terms of diagnosis and current height above and
below −2.0 SD, the US sample included only a few
GH-untreated patients, which affected the detection of
treatment-related group differences. Finally, the Qo-
LISSY score distribution in terms of standard deviation
and range as well as the scale effect size were compar-
able across Europe and the US, as was the instrument’s
ability to differentiate between groups based on height.
Because of differences in recruitment and sample com-
position, these differences cannot be interpreted to in-
dicate a comparable quality of life experience by
patient- and parent-observer report. More than scale-
based psychometric criteria, known group validity is
dependent on sample composition. Therefore, add-
itional studies in large and comparable samples are ne-
cessary to further evaluate the factor structure of the
Bullinger et al. Health and Quality of Life Outcomes  (2015) 13:43 Page 9 of 10US QoLISSY and the comparability of the measure
across countries.Conclusion
Results of pilot testing with focus group discussions and
cognitive debriefing show that HrQoL concepts are ad-
equately represented for the US population. Inspection
of the psychometric test criteria in terms of reliability
and validity indicate comparable performance of the
measure in the US and in Europe.
The cross-culturally applicable QoLISSY provides a step
forward in allowing measurement of the HrQoL impact of
short stature in children and adolescents and their par-
ents. It is now available for patients and parents in the US.
The instrument is fit for use to measure outcomes in clin-
ical trials and may be useful as well to assess treatment
outcomes in a clinical practice environment. Further re-
finement, additional validation in other languages and cul-
tures, migration to electronic platforms and development
of a shorter version of the QoLISSY questionnaire are
under consideration, to allow a broader use of the meas-
ure in children and adolescents with short stature from
their own and from their parents’ perspective.Access to the QoLISSY instrument
QoLISSY is a joint initiative between Pfizer Limited and
the University Medical Center Hamburg - Eppendorf.
Copyright Pfizer Limited all rights reserved. The European
QoLISSY instrument, together with comprehensive infor-
mation of its development and validation process is pub-
lished in the QoLISSY’s User’s Manual (Pabst Science
Publishers, Lengerich, 2013). The Manual, which is avail-
able upon request, includes QoLISSY child and parent
forms, as well as scoring information.
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